Patent Expiry
Patent/Exclusivity Expiry: VYONDYS 53
- Drug
- VYONDYS 53
Other upcoming events for SRPT
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of High Dos
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Transfer Therap
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Multinational, Open-label, Systemic Gene Delivery Study to Evaluate the Safety and Efficac
Patent ExpiryPatent/Exclusivity Expiry: AMONDYS 45
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multinational, Long-term Follow-up Study to Evaluate Safety and Efficacy in Subjects Who
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.